VivoSeq
Infectious Disease

Bacterial Infections

0

Pipeline Programs↗

5

Active Trials↗

6

Companies Involved↗

Bacterial Infections is an early-stage landscape with 0 programs across 6 companies. The most active players are Melinta Therapeutics, Inc., Pfizer, Roche.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Melinta Therapeutics, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalShionogi logo

Shionogi

0 programs

PreclinicalP

Paratek Pharmaceuticals Inc

0 programs

PreclinicalD

Dr. T. Perl

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed11 · 58%
Recruiting2 · 11%
Not yet recruiting2 · 11%
Active, not recruiting1 · 5%
Terminated1 · 5%
Approved for marketing1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

19 trials

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
Recruiting·Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 2·NCT06135350·234 enrolled
Use of Fosfomycin in the Treatment of Bacterial Infections
Recruiting·AAzienda Ospedaliera di Lecco·N/A·NCT06814899·300 enrolled
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Active, not recruiting·MMelinta Therapeutics, Inc.·Phase 1·NCT02687906·39 enrolled
Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT07382271·6 enrolled
Personalized Antibiotic Therapy - Point-of-Care Determination of Blood Levels of Beta-Lactam Antibiotics Using Coated-Blade-Spray Ion Mobility Spectrometry
Not yet recruiting·—·N/A·NCT07666230·200 enrolled
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000811·690 enrolled
Efficacy of Vitamin C on AKI Outcomes in Critically Ill Cirrhotics With Multidrug-resistant Bacterial Infections.
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04494451·100 enrolled
A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections
Completed·Roche logoRoche·Phase 1·NCT05614895·48 enrolled
Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections
Completed·Pfizer logoPfizer·Phase 1·NCT01015014·64 enrolled
The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections
Completed·—·N/A·NCT02848534·479 enrolled
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
Completed·Pfizer logoPfizer·Phase 1·NCT00678106·10 enrolled
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001318·60 enrolled
Prevention of Bacterial Infections in Newborn
Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT01800942·829 enrolled
Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
Completed·MMelinta Therapeutics, Inc.·Phase 1·NCT02134301·41 enrolled
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
Completed·PParatek Pharmaceuticals Inc·Phase 1·NCT05217537·23 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)